CGON insider trading
NasdaqGS HealthcareCG Oncology, Inc.: insider trade history from SEC Form 4 filings.
About CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Company website: cgoncology.com
CGON insider activity at a glance
FilingIQ tracks 90 insider transactions for CGON in filings since Jan 31, 2024. The most recent transaction is dated Sep 15, 2026.
Across the full history, 7 open-market purchases
and 43 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CGON insider trades is 63.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CGON Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding CGON
Frequently asked
- How many insider trades does FilingIQ track for CGON?
- FilingIQ tracks 90 Form 4 insider transactions for CGON (CG Oncology, Inc.), covering filings from Jan 31, 2024 onwards. 8 of those are dated within the last 90 days.
- Are CGON insiders net buyers or net sellers?
- Across the full Form 4 history for CGON, 7 transactions (8%) were open-market purchases and 43 (48%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CGON insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is CGON in?
- CG Oncology, Inc. (CGON) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.22B.
Methodology & sources
Every CGON insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.